Fred Aslan
President & Chief Executive Officer Artiva Biotherapeutics, Inc
Seminars
Wednesday 2nd December 2026
Deep B-Cell Depletion: Evolution From Early Proof-of-Concept To Registrational Trials
9:00 am
- How different companies in the field are playing to their strengths in choosing which indications to pursue in Phase III
- Using AlloNK as a case study, why Artiva opted to initiate a Phase III trial in rheumatoid arthritis based on the efficacy and safety data generated to date
- Lessons learned during clinical trials and from FDA interactions
Wednesday 2nd December 2026
Chair’s Opening Remarks – “From Promise to Reality: Advancing Cell Therapies Beyond Oncology”
8:25 am
Thursday 3rd December 2026
Chair’s Opening Remarks
8:50 am
Thursday 3rd December 2026
Chair’s Closing Remarks & End of Conference
4:00 pm
Wednesday 2nd December 2026
Chair’s Closing Remarks
4:30 pm
